||Hilton San Diego Bayfront Hotel
||Friday, June 1, 2012 4:45pm
||To register scroll down.
The CMSC, ACTRIMS, and NPA do not certify this program for Continuing Education Credit and do not take responsibility for the quality or evidence upon which the content has been based or the faculty chosen.
Multiple sclerosis is a complex disease with several mechanisms contributing to its pathophysiology. Early diagnosis and treatment is extremely important in MS because early intervention can help slow the disease process and the progression of disability. Biomarkers may be able to identify which processes are at work and hold promising value in the diagnosis and stratification of MS type, identification of disease stage, prediction of disease course, selection of treatment, detection of response to treatment, improvement of prognostic capabilities, and the evaluation of novel therapeutics. With recent advances in biomarkers research, MS clinicians must have the knowledge and skills to appropriately incorporate the use of biomarkers into MS diagnosis and treatment.
The goal of this educational program is to improve clinicians’ understanding of emerging molecular biomarkers in MS and provide a better understanding of how these markers are related to pathologic processes, disease activity, and clinical progression, in order to improve patient care and outcomes.
Francisco J. Quintana, MD (Chair)
Assistant Professor of Neurology
Center for Neurologic Diseases
Brigham and Women’s Hospital
Harvard Medical School
Aaron E. Miller, MD
Professor of Neurology and Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY
Suhayl Dhib-Jalbut, MD
Professor with Tenure and Chairman
Department of Neurology
UMDNJ-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ
This activity is intended for clinicians, neurologists, and other health care providers actively involved in the care of patients with multiple sclerosis.
This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Recognize the limitations of the current standard-of-care in MS and the need to incorporate biomarkers into management decisions
- Using biomarkers, develop algorithms to guide initiation and sequencing of disease-modifying therapy (DMT) for potential maximum impact
- Apply diagnostic biomarkers to allow for earlier diagnosis of MS
- Assess the clinical utility of biomarkers to monitor disease activity and response to DMT
|Registration and Dinner:
||4:45pm – 5:15pm
||5:15pm – 6:45pm
4:45 – 5:15pm
Registration and Dinner
|5:15 – 5:20pm
||Introduction and Welcome – Dr. Quintana
|5:20 – 5:40pm
||Need For Biomarkers in MS Care – Dr. Miller
|5:40 – 6:00pm
||Current Use of Biomarkers to Guide Therapy - Dr. Dhib-Jalbut
|6:00 – 6:20pm
||Emerging Biomarkers for Diagnosis and Surveillance – Dr. Quintana
|6:20 – 6:40pm
||Panel Discussion and Question & Answer Session – Faculty Panel
|6:40 – 6:45pm
||Summary and Concluding Remarks – Dr. Quintana
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, evaluation, please email email@example.com.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
METHOD OF PARTICIPATION
To complete this activity and receive credit, the participant must attend the program, and complete the evaluation form. A CME certificate will be mailed within 6-8 weeks.
There are no fees associated with this program.
Event staff will be glad to assist you with any special needs (e.g. physical, dietary, etc.). Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly Sponsored By
Supported by an educational grant from:
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.